Field Evaluation of Dried Blood Spots for HIV-1 Viral Load Monitoring in Adults and Children Receiving Antiretroviral Treatment in Kenya: Implications for Scale-up in Resource-Limited Settings
- 1 April 2017
- journal article
- conference paper
- Published by Ovid Technologies (Wolters Kluwer Health) in JAIDS Journal of Acquired Immune Deficiency Syndromes
- Vol. 74 (4), 399-406
- https://doi.org/10.1097/qai.0000000000001275
Abstract
Background: The World Health Organization recommends viral load (VL) as the preferred method for diagnosing antiretroviral therapy failure; however, operational challenges have hampered the implementation of VL monitoring in most resource-limited settings. This study evaluated the accuracy of dried blood spot (DBS) VL testing under field conditions as a practical alternative to plasma in determining virologic failure (VF). Methods: From May to December 2013, paired plasma and DBS specimens were collected from 416 adults and 377 children on antiretroviral therapy for >= 6 months at 12 clinics in Kenya. DBSs were prepared from venous blood (V-DBS) using disposable transfer pipettes and from finger-prick capillary blood using microcapillary tubes (M-DBS) and directly spotting (D-DBS). All samples were tested on the Abbott m2000 platform; V-DBS was also tested on the Roche COBAS Ampliprep/COBAS TaqMan (CAP/CTM) version 2.0 platform. VF results were compared at 3 DBS thresholds (>= 1000, >= 3000, and >= 5000 copies/mL) and a constant plasma threshold of >= 1000 copies/mL. Results: On the Abbott platform, at > 1000-copies/mL threshold, sensitivities, specificities, and kappa values for VF determination were >= 88.1%, >= 93.1%, and >= 0.82%, respectively, for all DBS methods, and it had the lowest percentage of downward misclassification compared with higher thresholds. V-DBS performance on CAP/CTM had significantly poorer specificity at all thresholds (1000%-33.0%, 3000%-60.9%, and 5000%-77.0%). No significant differences were found between adults and children. Conclusions: VL results from V-DBS, M-DBS, and D-DBS were comparable with those from plasma for determining VF using the Abbott platform but not with CAP/CTM. A 1000-copies/mL threshold was optimal and should be considered for VF determination using DBS in adults and children.Keywords
This publication has 26 references indexed in Scilit:
- Cross-Platform Analysis of HIV-1 RNA Data Generated by a Multicenter Assay Validation Study with Wide Geographic RepresentationJournal of Clinical Microbiology, 2012
- Challenges and opportunities for the implementation of virological testing in resource‐limited settingsJournal of the International AIDS Society, 2012
- Comparison of HIV-1 RNA Measurements Obtained by Using Plasma and Dried Blood Spots in the Automated Abbott Real-Time Viral Load AssayJournal of Clinical Microbiology, 2012
- Economic evaluation of monitoring virologic responses to antiretroviral therapy in HIV-infected children in resource-limited settingsAIDS, 2011
- Challenges in Implementing HIV Load Testing in South AfricaThe Journal of Infectious Diseases, 2010
- Switching to second-line antiretroviral therapy in resource-limited settings: comparison of programmes with and without viral load monitoringAIDS, 2009
- Monitoring HIV Antiretroviral Therapy in Resource‐Limited Settings: Time to Avoid Costly OutcomesClinical Infectious Diseases, 2009
- Running with Scissors: Using Antiretroviral Therapy without Monitoring Viral LoadClinical Infectious Diseases, 2008
- Evolution of drug resistance in HIV-infected patients remaining on a virologically failing combination antiretroviral therapy regimenAIDS, 2007
- HIV-1 Viral Load Assays for Resource-Limited SettingsPLoS Medicine, 2006